Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA567469
Title Hyaluronic Acid as a Target for Intervention in Prostate Cancer Metastases.
Publication Date Jun 2012
Media Count 22p
Personal Author S. S. Padalecki
Abstract Bone metastases are a debilitating and devastating complication for patients with advanced prostate cancer. Unfortunately, treatment options for patients with bone metastases are limited. Both hyaluronan synthase (HAS) and hyaluronic acid (HA) are upregulated in metastatic prostate cancer cells. 7- Hydroxy-4-Methyl Coumarin (HMC) is an inhibitor of hyaluronan synthase, commonly available in herbal supplements and, up to now, used mainly for digestion complaints. We proposed that it may be efficacious in the prevention and treatment of prostate cancer. Our hypothesis is that hyaluronic acid (HA) is utilized by prostate cancer cells to facilitate metastasis. Thus, reducing the production of HA should reduce the metastatic potential of prostate cancer cells making HA an ideal target for preventing and treating metastatic disease. The goal of this current research proposal is to determine whether reduction of HAS, via treatment with HMC, will prevent prostate cancer metastasis to bone and other organs or serve as a viable treatment for established bone metastasis. We have shown that HA protein levels in vitro correlate with metastatic potential and HA levels can be modulated in vitro using HMC. Furthermore, we have shown the in vitro growth of prostate cancer cells is slowed by inhibition of HA with HMC. In addition, we now have demonstrated that HMC can slow in vivo prostate cancer growth. We have observed modest effects of HMC on bone metastases. HMC appears have mild effects on preventing bone metastases. However, HMC had no effect on established bone metastases.
Keywords Cells(Biology)
Digestion(Biology)
Hyaluronate lyase
Metastasis
Organs(Anatomy)
Prostate cancer


 
Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Texas Univ. Health Science Center at San Antonio.
Document Type Technical report
Title Note Annual rept. 1 Jun 2008-31 May 2012.
NTIS Issue Number 1309
Contract Number W81XWH-08-1-0287

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader